Recursion clears IND for mutant-selective PI3Kα inhibitor REC-7735, ZINNIA Phase 1/2 to start in 2H26
Recursion, the AI-driven drug discovery company, said on 5 August 2026 that the US FDA has cleared its Investigational New Drug (IND) application for REC-7735 , a >100x mutant-selective PI3Kα H1047R inhibitor. The ZINNIA Phase 1/2 clinical study in patients with select PIK3CA H1047R-mutant solid tumours is due to begin in the second half of 2026.
REC-7735 is designed to enable deep suppression of the most common activating PI3Kα mutation while sparing wild-type PI3Kα, aiming to widen the therapeutic index versus earlier pan-PI3K approaches. The candidate was advanced through Recursion's machine-learning-driven discovery platform.
Recursion also reported that its lead internal programme REC-4881, a MEK1/2 inhibitor for familial adenomatous polyposis (FAP) carrying FDA Orphan Drug and Fast Track designations, will present updated Phase 1b/2 data at a hereditary-GI meeting in November 2026. Separately, partner Genentech optioned its first neuroscience target from the Recursion collaboration into an early discovery programme.
